Jacques Benkoski

Jacques Benkoski was already on his second acquisition when most venture capitalists were still writing their first term sheet. By the time he joined U.S. Venture Partners in 2005, he had co-founded a company that went public, run another one as CEO through a successful exit to Synopsys, and spent years in the trenches of European and American enterprise sales. The operational fingerprint shows in everything he does now.

USVP's General Partner desk in Menlo Park has become his twenty-year base for backing early-stage enterprise technology across the United States and Israel. His focus - cybersecurity, cloud infrastructure, data services, and enterprise SaaS - reflects not just market timing but a pattern: technical breakthroughs with defensible moats and founders who need a board member who has actually sold to enterprises before.

Benkoski was born in Belgium and completed his undergraduate engineering degree at the Technion - Israel Institute of Technology in 1985. He later crossed the Atlantic for graduate work at Carnegie Mellon, earning both his M.Sc. and Ph.D. in Computer Engineering in 1989. This tri-continental education is not a biographical detail - it is the infrastructure of his investing career: a deep technical foundation, a genuine connection to Israel's startup ecosystem, and the American enterprise market as his operating theater.

Early career stops at IBM's Scientific Center in Haifa and STMicroelectronics sharpened the research instincts. Then in the 1990s, Epic Design Technology called, and Benkoski took on the challenge of building its European subsidiary. Epic went public in 1994 - one of the earlier EDA company IPOs of that era. When Synopsys acquired it in 1997, Benkoski joined as Vice President of Strategic Sales. The cycle would repeat: build, scale, sell, iterate.

In 1998, Benkoski joined Monterey Design Systems as EVP of Sales and Marketing. Within a year he was running the company as President and CEO. Monterey was a physical design automation startup - exactly the kind of technically dense, defensible-IP business he would later specialize in funding. In 2004, Synopsys acquired Monterey, completing Benkoski's second exit to the same strategic acquirer. Pattern recognition was the product.

The decision to pivot to investing in 2005 was not a departure from operations - it was an extension. At USVP, he brought what most investors can only approximate through diligence calls: the direct experience of scaling a European startup, running a U.S. enterprise sales organization, and navigating multiple acquisition processes. His pitch to founders is grounded in that record.

Benkoski's board record at USVP tells a consistent story: find companies with genuine technical differentiation, help them navigate go-to-market, then hold through to meaningful acquisitions by strategic buyers. The list of acquirers - HPE, Cisco (twice), IBM, Dropbox, Symantec, Broadcom, VMware, Siemens, Synopsys (twice), Claroty - reads like a who's who of enterprise technology M&A.

Long before "Israeli cybersecurity" became a standard LP slide bullet point, Benkoski was already doing the work. His connection to the Israeli ecosystem goes beyond deal flow: he sits on the Board of Governors of the Technion - Israel Institute of Technology, his alma mater, and serves as Chairman Emeritus of the Silicon Valley Chapter of the American Technion Society. He is also on the steering committee of ICON, the Israel Collaboration Network.

The portfolio reflects this directly. Cato Networks, Hunters, AirEye, Ionix, Medigate (acquired by Claroty), Luminate (acquired by Symantec), Dune Networks (acquired by Broadcom) - these are Israeli-founded companies that needed a Silicon Valley-native board member who could navigate both worlds. Benkoski does not play the Israel card as a geographic thesis; he plays it as an information advantage built over decades.

Fluent in Hebrew in addition to English and French, he can engage in technical due diligence without a translator and bring founders into the USVP network without the usual cultural lag. In a market where every firm claims "deep Israel ties," Benkoski's are structural.

That line - "your biggest danger is an inbound" - is the kind of advice that sounds obvious until you unpack it. For Benkoski, the danger of an inbound lead is precisely its apparent effortlessness: founders who wait for opportunities to come to them stop building the proactive, scalable sales motion that enterprise companies actually require. His investing thesis is built on companies that earn their pipeline. The warning is not about any single deal. It is a philosophy about how markets get crossed.

That philosophy has a written form now. In 2025, Benkoski published "The Market Entry Strategy: Charting Your Course to Early Stage Venture Success" - a book drawn from a seminar he had already delivered to more than 5,000 entrepreneurs. The seminar predates the book by years. He built the audience before he wrote the manuscript.

There is a line in Jacques Benkoski's Twitter bio - active since April 2009, @JacBenko - that stops people mid-scroll: "passionate about building companies and working with non-assholes." In a professional network where every profile is a LinkedIn optimized highlight reel, this reads as a genuine value statement. It also happens to be a useful filter: founders who get it understand immediately what kind of board member they are getting.

Outside the boardroom and portfolio reviews, Benkoski is a competitive sailor - a pursuit that rewards exactly the blend of strategic patience and tactical aggression that venture capital requires. Sailing against competitors, like backing early-stage companies, involves committing to a course before the race is decided, reading conditions that others might miss, and knowing when to hold a line and when to tack.

At USVP, he has been part of the firm's institutional fabric for two decades. His investment range in recent funds sits between $6M and $12M per company at Series A stage - disciplined, high-conviction bets that allow for the close operational involvement his background enables. The $400M Fund XIII reflects a firm that has maintained its early-stage focus while scaling capital under management.